Kristin Brooks03.06.14
WuXi PharmaTech
4Q Revenues: $157.2 million (+25%)
4Q Earnings: $32.9 million (+38%)
FY Revenues: $578.1 million (+16%)
FY Earnings: $114.6 million (+32%)
Comments: Laboratory Services revenue in the quarter grew 15% to $119.4 million, driven by drug discovery and development services, with China-based revenues up 18% to $95.8 million, and U.S.-based revenues up 6% to $23.6 million. Manufacturing Services revenue was up 73% to $37.8 million, driven by strong demand in both research manufacturing and commercial manufacturing compared to 4Q12.
4Q Revenues: $157.2 million (+25%)
4Q Earnings: $32.9 million (+38%)
FY Revenues: $578.1 million (+16%)
FY Earnings: $114.6 million (+32%)
Comments: Laboratory Services revenue in the quarter grew 15% to $119.4 million, driven by drug discovery and development services, with China-based revenues up 18% to $95.8 million, and U.S.-based revenues up 6% to $23.6 million. Manufacturing Services revenue was up 73% to $37.8 million, driven by strong demand in both research manufacturing and commercial manufacturing compared to 4Q12.
